Robert Z. Orlowski

Robert Z. Orlowski is a Professor and Senior Researcher in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center. His research focuses on hematological malignancies, particularly multiple myeloma, encompassing immunology, pharmacology, and clinical transplantation. His recent work investigates minimal residual disease monitoring via mass spectrometry (EasyM) in patients receiving ciltacabtagene autoleucel, the impact of renal function on autologous stem cell transplantation outcomes in AL amyloidosis, and long-term outcomes of daratumumab-based regimens from the MAIA trial. He also leads the ADVANCE trial evaluating carfilzomib, lenalidomide, and dexamethasone with or without daratumumab, and studies gut microbiome correlates of response to idecabtagene vicleucel. His contributions span transplantation, radiation oncology, and novel therapeutic strategies in myeloma.